Invesco Ltd. Buys 24,466 Shares of United Therapeutics Co. (NASDAQ:UTHR)

Invesco Ltd. grew its stake in shares of United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 8.3% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 318,451 shares of the biotechnology company's stock after purchasing an additional 24,466 shares during the period. Invesco Ltd. owned approximately 0.71% of United Therapeutics worth $112,362,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Newbridge Financial Services Group Inc. bought a new position in shares of United Therapeutics in the 4th quarter worth about $25,000. Millstone Evans Group LLC purchased a new position in shares of United Therapeutics during the fourth quarter valued at approximately $67,000. MassMutual Private Wealth & Trust FSB grew its stake in shares of United Therapeutics by 31.9% in the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 240 shares of the biotechnology company's stock worth $85,000 after buying an additional 58 shares during the last quarter. Jones Financial Companies Lllp raised its stake in United Therapeutics by 678.9% during the fourth quarter. Jones Financial Companies Lllp now owns 296 shares of the biotechnology company's stock valued at $104,000 after buying an additional 258 shares during the last quarter. Finally, SBI Securities Co. Ltd. bought a new stake in United Therapeutics in the fourth quarter worth $131,000. Hedge funds and other institutional investors own 94.08% of the company's stock.

United Therapeutics Trading Down 0.2 %

NASDAQ UTHR traded down $0.48 on Thursday, hitting $284.71. 201,056 shares of the company traded hands, compared to its average volume of 452,746. The business's 50 day moving average price is $319.20 and its 200-day moving average price is $349.67. The company has a market capitalization of $12.79 billion, a price-to-earnings ratio of 12.50, a P/E/G ratio of 0.97 and a beta of 0.63. United Therapeutics Co. has a 52-week low of $232.84 and a 52-week high of $417.82.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last released its earnings results on Wednesday, February 26th. The biotechnology company reported $6.19 EPS for the quarter, topping analysts' consensus estimates of $6.10 by $0.09. The company had revenue of $735.90 million for the quarter, compared to analysts' expectations of $734.74 million. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. During the same quarter last year, the business earned $4.36 EPS. As a group, sell-side analysts predict that United Therapeutics Co. will post 24.48 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of equities analysts recently issued reports on the stock. StockNews.com cut shares of United Therapeutics from a "strong-buy" rating to a "buy" rating in a research note on Thursday, February 27th. UBS Group raised their price target on shares of United Therapeutics from $415.00 to $475.00 and gave the company a "buy" rating in a research report on Wednesday, January 8th. Finally, HC Wainwright reiterated a "buy" rating and set a $425.00 target price on shares of United Therapeutics in a research note on Thursday, February 27th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and ten have given a buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $388.25.

Insider Activity

In related news, Director Tommy G. Thompson sold 2,500 shares of the firm's stock in a transaction on Monday, March 24th. The shares were sold at an average price of $318.80, for a total value of $797,000.00. Following the completion of the transaction, the director now directly owns 8,480 shares of the company's stock, valued at approximately $2,703,424. This trade represents a 22.77 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, COO Michael Benkowitz sold 10,000 shares of the company's stock in a transaction on Monday, January 27th. The shares were sold at an average price of $370.71, for a total transaction of $3,707,100.00. Following the sale, the chief operating officer now directly owns 2,577 shares in the company, valued at approximately $955,319.67. The trade was a 79.51 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 80,500 shares of company stock worth $27,849,960 over the last ninety days. Corporate insiders own 11.90% of the company's stock.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.